Dura Pharmaceuticals
Executive Summary
FDA issues "not approvable" letter for Dura's Spiros albuterol inhaler. The agency is requesting additional clinical trials "to ensure inhaler reliability and to replicate the clinical outcomes of the initial trials," the company said Nov. 4. FDA has also asked the company to resolve certain chemistry, manufacturing and control issues